The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, today announced...
Building the Largest CMT Patient Data Set
CMTA has committed $206,000 over three years to support the Inherited Neuropathy Consortium (INC) in advancing CMT research. Since September 2022, this funding has sustained 20 clinical sites, supported over 20 scientific publications, and enabled large-scale natural history studies of CMT1B and CMT1X. With more than 7,000 patients enrolled, INC’s data set is critical for future clinical trials and Investigational New Drug (IND) approvals.
CMTA’s Commitment to The Inherited Neuropathy Consortium
CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic...
CMT2F Biomarkers and Outcome Measures
With CMTA support of $302,071, an international team of researchers from the Inherited Neuropathy Consortium...
2A Biomarkers and Outcome Measures
With CMTA support of $572,055, an international team of researchers from the Inherited Neuropathy Consortium,...
CMTX1 Biomarkers and Outcome Measures
With CMTA support of $529,971, an international team of researchers from the Inherited Neuropathy Consortium,...
1B Biomarkers and Outcome Measures
With CMTA support of $529,971, an international team of researchers from the Inherited Neuropathy Consortium,...
